Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Low-dose RSV mRNA vaccine
RSV mRNA vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Sinovac RSV mRNA vaccine low-dose group | EXPERIMENTAL | Participants will receive one dose of low-dose lyophilized RSV mRNA vaccine. |
| Sinovac RSV mRNA vaccine high-dose group | EXPERIMENTAL | Participants will receive one dose of high-dose lyophilized RSV mRNA vaccine. |
| Placebo control group | PLACEBO_COMPARATOR | Participants will receive one dose of normal saline. |
| Name | Type | Description |
|---|---|---|
| Low-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in low dosage |
| High-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in high dosage |
| Placebo | OTHER | Participants will receive one dose of normal saline. |
Inclusion Criteria: 1. Participants can understand and voluntarily sign the informed consent form; 2. Able to provide legal identity documents; 3. Healthy individuals aged 18 years and above; 4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contracepti...
Top 5 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 12 | PHASE3 | RSVpreF |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE2 | Bivalent RSV+HMPV protein vaccine, H5 influenza mRNA vaccine candidate, RSV mRNA vaccine candidate, Nirsevimab |
| Enanta Pharmaceuticals, Inc. | ENTA | 1 | PHASE2 | zelicapavir |
| Moderna, Inc. | MRNA | 2 | PHASE1 | mRNA-1345, mRNA-1365 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | RSV mRNA vaccine |
The RSV mRNA vaccine is an investigational vaccine developed by Sinovac Biotech, Ltd (ticker SVA) for respiratory syncytial virus, or RSV. It is an mRNA-based vaccine formulated as a lyophilized product and is currently in Phase 1 clinical development. It is not approved for use.
The RSV mRNA vaccine is being developed to prevent respiratory syncytial virus (RSV) infection. It is an investigational preventive vaccine, not a treatment for existing RSV illness, and it remains in Phase 1 testing. No approved indication exists for this candidate.
Sinovac Biotech, Ltd, which trades under the ticker SVA, is the developer of the RSV mRNA vaccine. The company is running the candidate through early clinical development, with one Phase 1 trial listed for the program.
The RSV mRNA vaccine is in Phase 1 clinical development. One Phase 1 trial has been registered and is currently active, with no completed trials for the program. The vaccine is investigational and has not been approved by any regulatory authority.
The RSV mRNA vaccine is being studied in trial NCT07418229, titled Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine. The Phase 1 trial is not yet recruiting, plans to enroll 60 healthy adult volunteers aged 18 years and older in China, and is randomized, double-blind, and placebo-controlled.
Yes. The low-dose RSV mRNA vaccine is another name for the RSV mRNA vaccine developed by Sinovac Biotech, Ltd (ticker SVA). Both names refer to the same Phase 1 investigational mRNA vaccine candidate for respiratory syncytial virus.